InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,214.43
(
-2.47%
)
US TECH 100
17,471.60
(
-2.67%
)
Dow Jones
38,828.19
(
-2.29%
)
Brent Oil
76.43
(
-0.91%
)
Bitcoin
54,639.27
(
-5.55%
)
Post# of 252786
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120210
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 97552

Tuesday, 07/20/2010 5:42:22 PM

Tuesday, July 20, 2010 5:42:22 PM

Post# of 252786
VRTX/BMY/GILD/VRUS/ITMN/IDIX: According to GILD’s 2Q10 today, the all-oral combination of GS9256 (a PI) and GS9190 (a non-nuke) is not producing adequate antiviral efficacy even when ribavirin is added to the mix.

GILD’s slip ought to be bullish for the other all-oral HCV players: VRTX, Roche/VRUS/ITMN, BMY, Boehringer Ingelheim, and IDIX.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up